Analyser av Vicore Pharma

Vicore: Redeye Ceases Coverage - Redeye

Redeye ceases its coverage of Vicore. Redeye will not provide research following quarterly reports or important business events for the comp...

Redeye • 24 feb 2023 15:09

Vicore Pharma: Directed Share Issue - Redeye

Redeye is overall positive to the news that Vicore has carried out a directed share issue of SEK 200 million.

Redeye • 08 dec 2022 12:12

Vicore: Additional IPF Data Reinforces Efficacy Signals - Redeye

Redeye is overall positive to the second interim analysis from Vicore’s phase II trial in IPF with drug candidate C21, that largely confirms...

Redeye • 04 nov 2022 08:44

Vicore: Our Q3 Comment - Redeye

Redeye comments on Vicore’s Q3 report, which came in as expected.

Redeye • 03 nov 2022 13:36

Vicore Pharma: Short comment on new ATRAG “C103” - Redeye

Redeye remains impressed by the rapid development of Vicore’s new generation of ATRAGs (angiotensin II type 2 receptor agonists) in its VP03...

Redeye • 13 okt 2022 08:43

Vicore: Promising data from Digital Therapy Pilot Phase - Redeye

Redeye is encouraged to learn that Vicore’s digital therapy “Almee” reduced anxiety by almost 50% in a pilot study (n=10) on IPF patients, a...

Redeye • 07 okt 2022 07:38

Vicore: Data from C21 Blood-flow Study Released - Redeye

We give a brief comment on the new blood-flow data from Vicore and the recent share price development.

Redeye • 27 sep 2022 08:30

Vicore: A comment on the Negative Covid-19 Phase III results - Redeye

Redeye gives a short comment on the Phase III Covid-19 results and reiterate our base case.

Redeye • 16 sep 2022 09:04

Vicore Pharma: Additional Update on IPF Program in Q4 - Redeye

Redeye is positive to the indication of continued strong performance in the ongoing phase II “AIR” trial in IPF, in line with the interim re...

Redeye • 02 sep 2022 11:33

Vicore Pharma: Our Q2 Comment - Redeye

Redeye comments on yesterday’s Q2 report from Vicore, which came in as expected.

Redeye • 26 aug 2022 07:51

Vicore Pharma: Positioned for the Top - Redeye

Redeye updates its view on Vicore following an eventful year for the company and its increasingly compelling pipeline.

Redeye • 23 maj 2022 10:36

Vicore Pharma: Our Q1 Report - Redeye

Redeye comments on the Q1 report from Vicore and give our view of recent events in the company.

Redeye • 05 maj 2022 12:20

Vicore: Initiates Blood Flow Study with C21 - Redeye

We give a brief comment on the new clinical study with Vicore’s C21.

Redeye • 18 mar 2022 12:37

Vicore Pharma: Clinical Study in New Indication (Pulmonary Arterial Hypertension) Announced - Redeye

Earlier today, Vicore announced that it will add a new indication for C21, the rare lung disease pulmonary arterial hypertension (PAH), and ...

Redeye • 09 mar 2022 10:56

Vicore Pharma: Our Q4 Comment - Redeye

Redeye comments on the Q4 report from Vicore and summarize our view of 2021.

Redeye • 25 feb 2022 11:06

Vicore Pharma: VP03 Ready for the Clinic - Redeye

Redeye is encouraged to learn about the progress with Vicore’s VP03 program and the acceleration of the first compound, C106, into clinic (a...

Redeye • 23 feb 2022 11:57

Vicore: Encouraging IPF Interim Data, Follow up - Redeye

Redeye gives an additional comment on yesterday’s interim data in Vicore’s phase II IPF study.

Redeye • 11 feb 2022 09:44

Vicore: Encouraging IPF Interim Data - Redeye

Redeye is encouraged by today’s interim data from Vicore’s open-label phase II study in IPF, which analysed 21 patients out of 60 expected t...

Redeye • 10 feb 2022 10:31

Vicore: First Patients Included in Pivotal C21 Covid-19 Trial - Redeye

We give a brief comment on the news that the first patients have been included in Vicore’s pivotal C21 Covid-19 Trial.

Redeye • 20 sep 2021 11:51

Vicore Pharma: Our Q2 Comment - Redeye

Redeye comments on the Q2 report from Vicore. We provide a brief comment on the financials and highlight the most important events during th...

Redeye • 26 aug 2021 13:29